Segulah Medical Acceleration

Protembis GmbH, established in 2017 and based in Aachen, Germany, specializes in the development of innovative surgical equipment, particularly focusing on minimally invasive medical devices. The company's flagship product, the ProtEmbo System, is an intra-aortic filter designed to mitigate the risk of cerebrovascular events during transcatheter aortic valve replacement (TAVR) procedures. This device effectively deflects embolic material generated during these cardiovascular interventions away from the cerebral circulation, thereby reducing the likelihood of brain injury. By enhancing the safety of TAVR, Protembis aims to improve patient outcomes, particularly as this procedure becomes more common among younger and lower-risk individuals. Through its advancements, Protembis is committed to increasing the quality of life for patients while also addressing the broader healthcare costs associated with complications arising from surgical interventions.

Collective Minds Radiology is a cloud-based healthcare company specializing in radiology services that facilitate collaboration and consultation among medical professionals. The company provides a platform that enables radiologists to share imaging cases with peers and access expert advice, thereby enhancing the diagnostic process. Their innovative workspace integrates collective intelligence and artificial intelligence, allowing healthcare professionals to improve clinical audits and maintain high-quality standards in imaging. This approach supports the creation of a comprehensive reference library for enhanced analysis and promotes continuous education and research within the field of radiology.

Navinci Diagnostics AB is a biotechnology company based in Uppsala, Sweden, specializing in biomolecular analysis for cancer and prenatal diagnostics. The company focuses on developing proprietary technology that facilitates the detection and quantification of proteins, their interactions, and modifications in various sample types, including tissue, cells, and blood. Navinci Diagnostics offers a range of products, including universal kits that can analyze cultured cells, fresh-frozen, and formalin-fixed paraffin-embedded (FFPE) samples, as well as target-specific kits that are pre-optimized for specific variables. Additionally, the company provides in-house immunostaining and custom assay services to enhance research and diagnostic capabilities.

Signifier Medical Technologies, headquartered in London, United Kingdom, develops and markets equipment designed to assist with sleep disorders. Founded in 2015 by Prof. Dr Anshul Sama, the company focuses on addressing the root cause of sleep-disordered breathing and snoring through innovative solutions. Their primary product is a flexible silicone device that uses low-intensity electrical pulses to train tongue muscles, aiming to prevent snoring and reduce mild sleep apnea symptoms. The company's brand name is Snoozeal.

Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its Allurion Program. This program features the Allurion Balloon, the world's first and only swallowable, procedure-less intragastric balloon designed to help overweight and obese patients achieve satiety, thereby reducing food intake and promoting weight loss. The balloon is administered to patients in the form of a capsule, allowing for a non-surgical, non-endoscopic, and anesthesia-free experience. In addition to the balloon, Allurion provides access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services, all aimed at enhancing the weight loss journey.

SAGA Diagnostics AB is a Swedish company specializing in personalized cancer diagnostics and disease monitoring through molecular genetic analyses, focusing on circulating tumor DNA (ctDNA). Founded in 2016 as a spin-out from a research group at Lund University, SAGA aims to enhance precision cancer medicine and improve patient survival rates with its minimally-invasive liquid biopsy testing services. The company provides a range of services, including gene mutation analysis and treatment monitoring, utilizing advanced technologies such as massively parallel sequencing. SAGA's proprietary tests enable oncologists and biopharmaceutical companies to detect actionable mutations, stratify patient groups, and monitor treatment responses with high sensitivity, thereby contributing significantly to advancements in cancer research and clinical diagnostics.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

CytaCoat is a private Swedish company based in the Karolinska Institutet Science Park in Solna, Stockholm. Founded by researchers from the Karolinska Institute and the Royal Institute of Technology, the company focuses on developing a proprietary antibacterial coating technology for medical devices. This innovative coating is designed to combat healthcare-associated infections by repelling problematic pathogenic bacteria without the use of antibiotics, thus minimizing the risk of antibiotic resistance. CytaCoat's technology is characterized by its stability under varying pH and ionic conditions, ensuring safety and effectiveness. The company operates a fully equipped laboratory for microbiological evaluation and optimization of its technology, and it has established collaborations with clinical partners such as the Karolinska University Hospital. Additionally, CytaCoat engages with regulatory consultants and clinical research organizations to guide its product development and commercialization efforts.

Vidya Health is the medical technology company based in London